(Q34095776)

31 July 2017

1 reference

title

Tyrosine kinase inhibitors: from rational design to clinical trials (English)

1 reference

31 July 2017

Traxler P

1

1 reference

31 July 2017

Bold G

2

1 reference

31 July 2017

Buchdunger E

3

1 reference

31 July 2017

Caravatti G

4

1 reference

31 July 2017

Furet P

5

1 reference

31 July 2017

Manley P

6

1 reference

31 July 2017

O'Reilly T

7

1 reference

31 July 2017

Wood J

8

1 reference

31 July 2017

Zimmermann J

9

1 reference

31 July 2017

1 November 2001

1 reference

Medicinal Research Reviews

31 July 2017

1 reference

31 July 2017

21

1 reference

31 July 2017

499-512

1 reference

31 July 2017

6

1 reference

Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors

31 July 2017

1 reference

Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones

21 January 2018

1 reference

Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and Src family tyrosine kinases

21 January 2018

1 reference

Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials

21 January 2018

1 reference

Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity

21 January 2018

1 reference

Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor

21 January 2018

1 reference

Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines

21 January 2018

1 reference

Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC).

21 January 2018

1 reference

Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases

21 January 2018

1 reference

Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials

21 January 2018

1 reference

Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions

21 January 2018

1 reference

Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis

21 January 2018

1 reference

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.

21 January 2018

1 reference

Abl tyrosine kinase in signal transduction and cell-cycle regulation

21 January 2018

1 reference

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

21 January 2018

1 reference

Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411

21 January 2018

1 reference

Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor

21 January 2018

1 reference

Vascular endothelial growth factor

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MED.1022

1 reference

31 July 2017

1 reference